Cipla Limited

“Cipla's India branded-respiratory franchise is a genuine, durable business with structural tailwinds — but it is priced as though the North America complex-generics pivot will succeed, when that outcome remains unproven after years of underdelivery. FY2026 delivered a 26% net profit decline and a 75% FCF collapse on doubling capex, and yet the stock trades at 22x forward earnings that already embed a full recovery. With ROE at 11.7%, no margin of safety, and a capex cycle that has yet to demonstrate returns, Cipla offers below-average risk of permanent capital loss but equally below-average prospects for above-average long-term returns from today's price. TRACK: re-enter on price correction to 17–18x forward or on demonstrated North America traction.”